Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-711-1 | CAS number: 148-24-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Propylene glycol solution for 8-hydroxyquinoline was administered intravenously through the femoral vein. Bile and urine samples were collected at approproate time intervals until 8 hr through polyethylene tubes set into bile duct, i.e bile fistula, and bladder, respectively. After 14C-8-hydroxyquinoline in propylene glycol solution 4.86 mg containing 10.1 uCi per head was administered intravenously, blood samples were collected from femoral artery through polyethylene cannula at appropriate time intervals until 4 hr.
- GLP compliance:
- no
- Radiolabelling:
- yes
- Species:
- rat
- Strain:
- other: Dondryu
- Sex:
- male
- Route of administration:
- intraperitoneal
- Vehicle:
- propylene glycol
- Dose / conc.:
- 15 mg/kg bw/day (nominal)
- No. of animals per sex per dose / concentration:
- Three
- Control animals:
- no
- Type:
- absorption
- Results:
- Intraperitoneal administration of 8-hydroxyquinoline showed rapid absorption in all animals at 8 h (>80%) based on urinary excretion.
- Type:
- metabolism
- Results:
- Glucuronide about 65% of dose and suphate about 25% of dose. No hydrolysis of the 8- hydroxyquinoline main metabolites occurred in vivo.
- Type:
- excretion
- Results:
- 82.8% of the test material was eliminated in urine and 8.7% in bile within 8 h.
- Details on absorption:
- Intraperitoneal administration of 8-hydroxyquinoline showed rapid absorption in all animals at 8 h (>80%) based on urinary excretion.
- Details on excretion:
- 82.8% of the test material was eliminated in urine and 8.7% in bile within 8 h.
- Metabolites identified:
- yes
- Details on metabolites:
- Glucuronide about 65% of dose and suphate about 25% of dose. No hydrolysis of the 8- hydroxyquinoline main metabolites occurred in vivo.
- Executive summary:
Two metabolites were found in male rat urine and bile after intravenous administration of 15 mg/kg bw of 8-hydroxyquinoline within 8 hours. 8-hydroxyquinoline glucuronide conjugate was collected in urine (59.9%) and bile (8.7%) and 8-hydroxyquinoline sulphate accounted for only in urine (22.9%). Unmetabolized 8-hydroxyquinoline was hardly detected both in urine and bile.
The fate of the in vivo glucuronide conjugate was followed after intravenous administration to rats and about 90% and 10% of the dose were excreted in urine as the same conjugate. In the same way the sulphate metabolite was administered intravenously in vivo and 95% was detected in urine but not in bile. These results showed that no hydrolysis of the 8- hydroxyquinoline main metabolites occurred in vivo.
Reference
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 80
Additional information
From CLH report:
All the toxicokinetic data available were obtained from rat studies.
Absorption: Rapidly absorbed from gastrointestinal tract after single oral administration of 10
mg/kg bw of 8-hydroxyquinoline in all animals at 8 h (>80%) based on urinary excretion. Excretion: Most of the radioactivity was eliminated by urine (80.0-79.6%) and faeces (3.7-
4.0%) at 8 h after a single oral administration of 10 mg/kg bw in males-females respectively. At 120 h recovery for both sexes was almost complete. The administered radioactivity was excreted with a half-life of 28 min after oral administration and of 34 min after intravenous administration. After intravenous administration of 15 mg/kg bw of 8-hydroxyquinoline to male rats with bile fistula, 82.8% of the test material was eliminated in urine and 8.7% in bile within 8 h.
Distribution: Radioactivity in the tissues was observed at marginal levels only at 72 h after oral administration. The greatest concentration found in tissues was in spleen (0.152%),
kidneys (0.055%) and liver (0.033%). Mean plasma radioactivity concentrations was observed in all animals after single oral and intravenous administrations of 10 mg/kg bw at 15
min and at 5 min respectively. All available data indicate that there was no accumulation in tissues. The systemic bioavailability of plasma radioactivity following oral administration of [14C]-8- hydroxyquinoline was 63.4% of that following intravenous administration.
Metabolism: Two metabolites were found in male rat urine and bile after intravenous administration of 15 mg/kg bw of 8-hydroxyquinoline within 8 hours. 8-hydroxyquinoline
glucuronide conjugate was collected in urine (59.9%) and bile (8.7%) and 8-hydroxyquinoline sulphate accounted for only in urine (22.9%). Unmetabolized 8-hydroxyquinoline was hardly detected both in urine and bile. Enterohepatic circulation of 8-hydroxyquinoline was confirmed when the bile of one rat was infused to the duodenum of another one and both main metabolites were present in urine showing reabsorption of glucuronide conjugate. The fate of the in vivo glucuronide conjugate was followed after intravenous administration to
rats and about 90% and 10% of the dose were excreted in urine as the same conjugate. In the same way the sulphate metabolite was administered intravenously in vivo and 95% was detected in urine but not in bile. These results showed that no hydrolysis of the 8- hydroxyquinoline main metabolites occurred in vivo.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.